- Home
- JBHT vs BIIB Comparison
JBHT vs BIIB Comparison
Compare JBHT & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBHT
- BIIB
- Stock Information
- Founded
- JBHT 1961
- BIIB 1978
- Country
- JBHT United States
- BIIB United States
- Employees
- JBHT N/A
- BIIB N/A
- Industry
- JBHT Trucking Freight/Courier Services
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- JBHT Industrials
- BIIB Health Care
- Exchange
- JBHT Nasdaq
- BIIB Nasdaq
- Market Cap
- JBHT 15.7B
- BIIB 18.7B
- IPO Year
- JBHT N/A
- BIIB 1991
- Fundamental
- Price
- JBHT $169.73
- BIIB $151.67
- Analyst Decision
- JBHT Buy
- BIIB Buy
- Analyst Count
- JBHT 18
- BIIB 23
- Target Price
- JBHT $168.72
- BIIB $173.25
- AVG Volume (30 Days)
- JBHT 1.7M
- BIIB 1.5M
- Earning Date
- JBHT 10-15-2025
- BIIB 10-30-2025
- Dividend Yield
- JBHT 1.04%
- BIIB N/A
- EPS Growth
- JBHT 5.00
- BIIB N/A
- EPS
- JBHT 5.77
- BIIB 10.97
- Revenue
- JBHT $12,048,818,000.00
- BIIB $10,065,900,000.00
- Revenue This Year
- JBHT $1.34
- BIIB $2.97
- Revenue Next Year
- JBHT $3.80
- BIIB N/A
- P/E Ratio
- JBHT $29.39
- BIIB $13.80
- Revenue Growth
- JBHT N/A
- BIIB 4.77
- 52 Week Low
- JBHT $122.79
- BIIB $110.04
- 52 Week High
- JBHT $200.40
- BIIB $179.20
- Technical
- Relative Strength Index (RSI)
- JBHT 67.94
- BIIB 58.47
- Support Level
- JBHT $163.71
- BIIB $138.00
- Resistance Level
- JBHT $171.52
- BIIB $151.91
- Average True Range (ATR)
- JBHT 4.75
- BIIB 4.70
- MACD
- JBHT 0.53
- BIIB 0.22
- Stochastic Oscillator
- JBHT 92.00
- BIIB 78.86
About JBHT J.B. Hunt Transport Services Inc.
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (48% of sales), dedicated trucking services that provide customer-specific fleet needs (27%), for-hire truckload (6%), heavy goods final-mile delivery (7%), and asset-light truck brokerage (12%).
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.